Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Learn more

  • Federal grantsHow to Find Grants for Nonprofits
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to apply for a grantGrant Applications vs. RFPs: Writing Differences Explained
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Closed bids
  3. ›Federal
  4. ›Single Cell Opioid Responses in the Context of HIV…

U.S. National Institutes of Health·United States of America

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed)

Closes 11/20/2025$275kGrants Notice
Bid source

This opportunity has closed.

Bid Banana tracks 1.6M+ bids and awards across all 50 states. Save a search and we'll email your new matches, daily or weekly — so the next one reaches you with time to bid.

Get alerted next time

Description

The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. * The opportunity is for research in the context of HIV and Substance Use Disorder * The focus is on single cell data sets and their analysis * The grant will support data mining and functional validation studies * The grant is not allowed for clinical trials * The award ceiling is $275,000

Attached files

Contact

[email protected]

Key dates

Opened
8/14/2024
Closes
11/20/2025

Last updated

Details

Type
Grants Notice
Industry
Healthcare and Medical Services
NAICS
541710
Solicitation №
RFA-DA-26-002

Budget estimate

$275,000

The Award Ceiling is explicitly stated on the source site.

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one too late. Don't find the next one too late.

Bid Banana searches open government bids across all 50 states, updated daily. Save a search once and we email you your new matches, daily or weekly, while there is still time to win them.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 83%

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2

Closes 6/7/2027Opened 8/20/2026

U.S. National Institutes of Health·United States of America

74% match

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

Closes 12/3/2027Opened 12/5/2024

U.S. National Institutes of Health·United States of America

73% match

Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)

Closes 10/28/2027Opened 6/9/2025

U.S. National Institutes of Health·United States of America

72% match

Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)

Closes 11/16/2027Opened 1/8/2025

U.S. National Institutes of Health·United States of America

72% match

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

Closes 3/6/2027Opened 8/2/2024

U.S. National Institutes of Health·United States of America

72% match

Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)

Closes 3/16/2027Opened 1/8/2025

U.S. National Institutes of Health·United States of America

72% match

HIV/AIDS Clinical Trials Network Statistical and Data Management Centers

Closes 1/21/2027Opened 4/8/2026

U.S. National Institutes of Health·United States of America

71% match

HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)

Closes 2/9/2029Opened 6/4/2026

U.S. National Institutes of Health·United States of America

71% match

Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional)

Closes 7/16/2029Opened 1/26/2026

U.S. National Institutes of Health·United States of America

71% match

Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)

Closes 12/3/2027Opened 12/5/2024

U.S. National Institutes of Health·United States of America

70% match

Implementation and Evaluation of Databases to Examine AIDS

Closes 5/26/2027Opened 5/27/2025

U.S. National Institutes of Health·United States of America

70% match

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Closes 11/18/2027Opened 11/20/2024

U.S. National Institutes of Health·United States of America

70% match

AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)

Closes 5/24/2027Opened 6/24/2026

U.S. National Institutes of Health·United States of America

70% match

High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)

Closes 3/5/2027Opened 1/17/2024

U.S. National Institutes of Health·United States of America

70% match

HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)

Closes 1/15/2027Opened 9/18/2024

U.S. Food and Drug Administration·United States of America

70% match

Cooperative Agreement to Support Activities Related to Analgesics, Anesthetics, and Addiction (U01) Clinical Trials Allowed

Rolling / TBD closeOpened 8/14/2024

U.S. National Institutes of Health·United States of America

70% match

Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV/AIDS Research (U42 Clinical Trial Not Allowed)

Closes 1/24/2027Opened 5/20/2026

U.S. National Institutes of Health·United States of America

69% match

Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional)

Closes 3/16/2029Opened 9/10/2025

U.S. National Institutes of Health·United States of America

69% match

HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)

Closes 9/6/2027Opened 10/1/2026

U.S. National Institutes of Health·United States of America

69% match

HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)

Closes 1/26/2027Opened 7/17/2025

U.S. National Institutes of Health·United States of America

69% match

Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)

Closes 6/20/2029Opened 11/18/2025

U.S. Centers for Disease Control and Prevention - ERA·United States of America

69% match

Improving Linkage to Care for People with Opioid Use Disorder (U01)

Closes 12/30/2026Opened 7/2/2026

U.S. National Institutes of Health·United States of America

69% match

Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)

Closes 11/5/2027Opened 1/8/2025

U.S. National Institutes of Health·United States of America

69% match

Immune Tolerance Network (UM1 Clinical Trial Required)

Closes 1/29/2027Opened 6/24/2026

U.S. National Institutes of Health·United States of America

69% match

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Closes 2/20/2029Opened 5/28/2025